The COVID-19 pandemic highlighted industry-level weaknesses in the inbound supply chain structure and function and has intensified existing failures that allow demand to outstrip suppliers’ capacity and capability to support industry’s growth.
If industry is to adjust to the new normal as it moves from ‘pandemic to endemic’, it needs to help solve the most important issues over an appropriate timeframe, and strengthen and advance inbound supply chain operations to benefit patients globally.
BioPhorum Supply Partner members felt industry needed a strategy to help develop the inbound supply chain and improve its operational excellence. So the Phorum decided to ‘own’ this action and created the Biopharmaceutical Manufacturing Industry Inbound Supply Chain Strategic Framework, which it launched in June 2021.
Building on the original Strategic Framework, this new document explains how it should be used.
It includes a maturity/capability model to help companies identify how to develop so they can increase their maturity/capability level for any of the five strategic objectives. It is based on shared ‘real-world evidence’ from members who have contributed to how they achieve the level they are at with the people (organizations), systems (technologies) and process (operating procedures) they have invested in.
Created in partnership with biomanufacturers and suppliers, it is already being used by BioPhorum members. It is also helping to guide the Phorum’s collaborative approach to solving some of industry’s most important inbound supply chain issues over the next two to five years and raising standards globally.